BR112023025188A2 - Métodos de uso de anticorpos anti-sortilina - Google Patents

Métodos de uso de anticorpos anti-sortilina

Info

Publication number
BR112023025188A2
BR112023025188A2 BR112023025188A BR112023025188A BR112023025188A2 BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2 BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A BR112023025188 A BR 112023025188A BR 112023025188 A2 BR112023025188 A2 BR 112023025188A2
Authority
BR
Brazil
Prior art keywords
sortilin
methods
antibodies
sortilin antibodies
matured
Prior art date
Application number
BR112023025188A
Other languages
English (en)
Portuguese (pt)
Inventor
C Mangal Brian
Leejia Yeh Felix
Y Huang Julie
F Ward Michael
Rizwan Siddiqui Omer
Robert Paul
Sam Jackson
Whedy Wang
Yijie Liao
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of BR112023025188A2 publication Critical patent/BR112023025188A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112023025188A 2021-06-08 2022-06-08 Métodos de uso de anticorpos anti-sortilina BR112023025188A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163208238P 2021-06-08 2021-06-08
US202163209360P 2021-06-10 2021-06-10
US202163225916P 2021-07-26 2021-07-26
US202163277069P 2021-11-08 2021-11-08
US202263304522P 2022-01-28 2022-01-28
US202263311379P 2022-02-17 2022-02-17
PCT/US2022/072827 WO2022261648A2 (en) 2021-06-08 2022-06-08 Methods of use of anti-sortilin antibodies

Publications (1)

Publication Number Publication Date
BR112023025188A2 true BR112023025188A2 (pt) 2024-02-27

Family

ID=84426402

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025188A BR112023025188A2 (pt) 2021-06-08 2022-06-08 Métodos de uso de anticorpos anti-sortilina

Country Status (6)

Country Link
US (1) US20240132597A1 (cg-RX-API-DMAC7.html)
EP (1) EP4351728A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526060A (cg-RX-API-DMAC7.html)
BR (1) BR112023025188A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220428A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022261648A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
WO2025031098A1 (zh) * 2023-08-09 2025-02-13 瑞诺元(苏州)生物科技有限公司 一种分拣蛋白1特异性的纳米抗体、含有其的重组aav及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119679944A (zh) * 2018-01-25 2025-03-25 渤健马萨诸塞州股份有限公司 治疗脊髓性肌萎缩症的方法
EP3983441A1 (en) * 2019-06-11 2022-04-20 Alector LLC Anti-sortilin antibodies for use in therapy

Also Published As

Publication number Publication date
JP2024526060A (ja) 2024-07-17
EP4351728A4 (en) 2025-08-27
WO2022261648A3 (en) 2023-01-19
EP4351728A2 (en) 2024-04-17
US20240132597A1 (en) 2024-04-25
WO2022261648A2 (en) 2022-12-15
CA3220428A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112022019892A2 (pt) Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
CR20200566A (es) Anticuerpos anti-sirpa y metodos de utilización de los mismos
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
EA201792221A1 (ru) Антитела против сортилина и способы их применения
BR112018074847A2 (pt) anticorpos específicos anti hla-g
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
BR112022001733A2 (pt) Anticorpos anti-ms4a4a e métodos de uso dos mesmos
BR112023025188A2 (pt) Métodos de uso de anticorpos anti-sortilina
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
MX2024010324A (es) Metodos de uso de anticuerpos anti-trem2.
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
CL2022003296A1 (es) Anticuerpos anti-cd200r1 y métodos de uso de los mismos
BR112022011337A2 (pt) Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
AR122237A1 (es) Anticuerpos anti-sortilina y métodos para su uso